Effects of amide local anaesthetics on eicosanoid formation in burned skin.
BACKGROUND
Previous studies have demonstrated potent inhibition of burn oedema and progressive ischaemia by local anaesthetics. Since eicosanoids have been suggested to play an important role in the pathophysiology of burns, we compared in the present ex vivo study the effects of topical lidocaine/prilocaine cream (EMLA, ASTRA, Sweden) and intravenous lidocaine with that of saline on eicosanoid formation by normal and burned rat skin.


METHODS
A full-thickness burn trauma was induced in the abdominal skin. All the agents were given 5 min postburn until 2 h after the trauma. The experimental skin was subsequently removed and incubated in Krebs solution for 1 h. Eicosanoid concentrations in the solution were analysed by radioimmunoassay.


RESULTS
EMLA cream induced a significant inhibition of TXB2 (P<0.05) and 6-Keto-PGF1alpha (P<0.01) but not of PGE release from burned skin as compared to saline treatment. Intravenous lidocaine infusions did not significantly influence the release of any of the measured eicosanoids versus saline.


CONCLUSIONS
In conclusion, the lack of effect of intravenous lidocaine could relate to the severe burn trauma inducing rapid ischaemia which may have interfered with the delivery of the agent to the burned tissues or to insufficient concentrations achieved in the burn area. Topical treatment of burned skin with a local anaesthetic cream significantly reduced the release of TXB2 and 6-Keto-PGF1alpha, suggesting a possible mechanism of action in progressive burn ischaemia.
Jönsson
A
A
Department of Physiology and Institution of Surgical Specialities, Göteborg University, Sweden.
Cassuto
J
J
Tarnow
P
P
Sinclair
R
R
Bennett
A
A
Tavares
I A
IA
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000287:Administration, Topical; D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D002056:Burns / Q000378:metabolism*; D015777:Eicosanoids / Q000096:biosynthesis*; D007262:Infusions, Intravenous; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology; D000077442:Lidocaine, Prilocaine Drug Combination; D008297:Male; D009824:Ointments; D011318:Prilocaine / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D013929:Thromboxane B2 / Q000096:biosynthesis
D000779:Anesthetics, Local; D015777:Eicosanoids; D000077442:Lidocaine, Prilocaine Drug Combination; D009824:Ointments; D011318:Prilocaine; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D008012:Lidocaine